Life Science Investing Bristol Myers Squibb Announces Accepted Amounts and Pricing Terms of its Tender Offers
Life Science Investing Bristol Myers Squibb Announces Early Participation Results, Amendment and Early Settlement of Tender Offers
Life Science Investing Sarah Cannon Research Institute and Bristol Myers Squibb Expand Strategic Collaboration to Accelerate Patient Enrollment and Broaden Access to Innovative Cancer Research
Life Science Investing Bristol Myers Squibb Showcases New Long-Term and Real-World Data From Cardiovascular Portfolio at the American Heart Association Scientific Sessions 2025
Life Science Investing Bristol Myers Squibb Presents Encouraging Data from Phase 1 Breakfree-1 Study of CD19 NEX-T CAR T Cell Therapy in Three Chronic Autoimmune Diseases at ACR Convergence 2025
Life Science Investing SystImmune, Inc. and Bristol Myers Squibb Announce First Global Phase I Results of Iza-bren, an EGFR x HER3 Bispecific Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors at ESMO 2025
Life Science Investing Bristol Myers Squibb to Present Data at ESMO® 2025 Showcasing Progress of Oncology Portfolio Across Diverse Tumor Types
Life Science Investing SystImmune to Receive Milestone Payment from Bristol Myers Squibb Under Iza-Bren Collaboration
Life Science Investing Bristol Myers Squibb Strengthens and Diversifies Cell Therapy Portfolio with Acquisition of Orbital Therapeutics
Life Science Investing Bristol Myers Squibb and TV Host Gail Simmons Tackle Stigma in Schizophrenia with New Initiative Spotlighting the Power of Support and Connection
Life Science Investing Bristol Myers Squibb's Anti-MTBR-Tau-Targeting Antibody, BMS-986446, Granted Fast Track Designation by U.S. FDA for the Treatment of Alzheimer's Disease
